Welcome! Login | Register
 

Guilty Pleasures for When the Kids Go Back to School—Now that the kids have returned to school,…

Patriots Tame Panthers For Blowout Home Win—The New England Patriots defeated the Carolina Panthers…

Friday Financial Five - August 22, 2014—Little bundles of joy are considered priceless, but…

Mom Can-Do’s: Run! Jump! Fly-days! at the EcoTarium and More!—Moms of little ones—from toddlers to elementary schoolers—looking…

Artist Tory Fair to Speak At Worcester Art Museum—Contemporary artist Tory Fair will discuss her work,…

Patriots Roster Projections 2.0—Who makes the cut? Who gets cut? Find…

Old Sturbridge Village to Offer Free Admission to Kids on Labor Day Weekend—Old Sturbridge Village will host their annual "Family…

Worcester to Declare August 21 as American Antiquarian Society Day—City officials and American Antiquarian Society staff will…

Organize + Energize: 10 Ways to Make Your Mornings Easier—How many of you rush around in the…

Dear John: Does He Have a Secret Life?—She found lipstick in his car.....

 
 
Tracker Pixel for Entry

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.